Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to evaluate the effect of natalizumab exposure on pregnancy outcomes and disease activity during pregnancy

Next Previous
Trial Profile

A study to evaluate the effect of natalizumab exposure on pregnancy outcomes and disease activity during pregnancy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 07 Feb 2018 Results (n=83) assessing the risk of disease reactivation during pregnancy after natalizumab suspension compared with untreated patients and patients treated with injectable immunomodulatory agents published in the Neurology
  • 07 Feb 2018 Results (n=83) assessing fetal risk after pregnancy exposure to natalizumab in women with multiple sclerosis compared with untreated patients and patients treated with injectable immunomodulatory agents published in the Neurology
  • 21 Apr 2016 Safety results (n=59) of natalizumab exposed pregnancies in MS patients compared with the Italian dataset of interferon-beta (IFNB) exposed and non-exposed pregnancies were presented at the 68th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top